Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

BACKGROUND: Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the killing capacity of γδ T cells, which are critic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Ji, Niannian, Mukherjee, Neelam, Reyes, Ryan M, Gelfond, Jonathan, Javors, Martin, Meeks, Joshua J., McConkey, David J, Shu, Zhen-Ju, Ramamurthy, Chethan, Dennett, Ryan, Curiel, Tyler J, Svatek, Robert S
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7929866/
https://ncbi.nlm.nih.gov/pubmed/33653802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001941
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados